CSDX Net Income Jumps 150% on Cost Cuts, Revenue Dips 28%

TL;DR

**CSDX is a high-risk bet: impressive cost control boosted net income, but plummeting revenue and a 'going concern' warning make it a speculative play reliant on continuous shareholder infusions.**

AI Summary

CS DIAGNOSTICS CORP. (CSDX) reported a net income of $32,263 for the six months ended June 30, 2025, a significant increase from $12,912 in the prior-year period. This improvement was driven by a substantial reduction in total operating expenses, which decreased to $38,887 from $85,505 in the same period of 2024, primarily due to lower professional fees. However, total revenues declined by approximately 28%, falling to $71,150 for the six months ended June 30, 2025, from $98,417 in 2024, attributed to reduced diagnostic service activity and lower one-time licensing income. The company's cash position remains extremely low at $196 as of June 30, 2025, down from $501 at December 31, 2024. Despite the low cash, total assets increased slightly to $499,431,377 from $499,400,501, largely due to intangible assets valued at $499,400,000. The company eliminated all current liabilities, reporting $0 as of June 30, 2025, compared to $1,428 at year-end 2024. CSDX continues to rely on shareholder support and external financing to meet its capital requirements, with a going concern warning due to an accumulated deficit of $(4,735,665).

Why It Matters

For investors, CSDX's ability to significantly cut operating expenses and achieve a 150% increase in net income, despite a 28% revenue decline, signals a focus on efficiency but raises questions about top-line growth sustainability. The company's reliance on shareholder support and external financing, coupled with a 'going concern' warning, indicates high financial risk, potentially impacting future stock performance and employee stability. In a competitive medical diagnostics market, declining revenue could hinder CSDX's ability to innovate and expand, affecting its long-term viability and market position. Customers might face uncertainty regarding service continuity if the company struggles to secure consistent funding.

Risk Assessment

Risk Level: high — The company explicitly states a 'going concern' warning due to an accumulated deficit of $(4,735,665) as of June 30, 2025, and extremely low cash of $196. Its ability to continue operations is dependent on 'improving profitability and the continuing financial support from its stockholders,' indicating significant financial instability.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Monitor future filings closely for sustained revenue growth and a stronger cash position, as the current financial health relies heavily on external capital infusions.

Financial Highlights

debt To Equity

0.0

revenue

$71,150

operating Margin

45.2%

total Assets

$499,431,377

total Debt

$0

net Income

$32,263

eps

$0.00

gross Margin

N/A

cash Position

$196

revenue Growth

-28%

Revenue Breakdown

Key Numbers

• $32,263 — Net Income (6 months) (Increased from $12,912 in prior year, a 150% rise.)
• $71,150 — Revenue (6 months) (Decreased by 28% from $98,417 in prior year.)
• $38,887 — Operating Expenses (6 months) (Decreased significantly from $85,505 in prior year.)
• $196 — Cash (Extremely low, down from $501 at year-end 2024.)
• $499.4M — Intangible Assets (Primary component of total assets, stable from prior period.)
• $0 — Total Liabilities (Reduced from $1,428 at year-end 2024, indicating improved current balance sheet.)
• $(4.74M) — Accumulated Deficit (Indicates ongoing losses and contributes to going concern doubt.)
• $(345) — Net Cash Used in Operating Activities (Negative cash flow from core operations for the six months.)
• $499.4M — Net Cash Provided by Financing Activities (Reflects significant equity infusions to cover investing activities.)
• 137,340,200 — Common Shares Outstanding (As of June 30, 2025.)

Key Players & Entities

• CS DIAGNOSTICS CORP. (company) — registrant
• $32,263 (dollar_amount) — net income for six months ended June 30, 2025
• $12,912 (dollar_amount) — net income for six months ended June 30, 2024
• $71,150 (dollar_amount) — total revenues for six months ended June 30, 2025
• $98,417 (dollar_amount) — total revenues for six months ended June 30, 2024
• $38,887 (dollar_amount) — total operating expenses for six months ended June 30, 2025
• $85,505 (dollar_amount) — total operating expenses for six months ended June 30, 2024
• $196 (dollar_amount) — cash and cash equivalents as of June 30, 2025
• $501 (dollar_amount) — cash and cash equivalents as of December 31, 2024
• $(4,735,665) (dollar_amount) — accumulated deficit as of June 30, 2025

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company has an accumulated deficit of $(4,735,665) and extremely low cash reserves of $196 as of June 30, 2025. This raises substantial doubt about its ability to continue as a going concern, necessitating reliance on shareholder support and external financing.
• Dependence on External Financing [high — financial]: CSDX relies heavily on shareholder support and external financing to meet its capital requirements. This dependence creates vulnerability to changes in investor sentiment and the availability of funding.
• Revenue Decline [medium — operational]: Total revenues decreased by 28% to $71,150 for the six months ended June 30, 2025, from $98,417 in the prior year. This decline was driven by reduced diagnostic service activity and lower one-time licensing income.
• Low Cash Position [high — financial]: The company's cash balance is critically low at $196 as of June 30, 2025, down from $501 at year-end 2024. This severely limits operational flexibility and the ability to meet short-term obligations without external funding.
• Significant Intangible Assets [medium — financial]: Intangible assets constitute the vast majority of total assets at $499,400,000. The valuation and realizability of these assets are crucial for the company's financial health, though they are stable from the prior period.

Industry Context

CS Diagnostics Corp. operates in the medical technology sector, focusing on diagnostic and therapeutic products. The industry is characterized by innovation, regulatory oversight, and the need for significant R&D investment. Companies often collaborate with research institutions and healthcare professionals to bring new technologies to market.

Regulatory Implications

As a medical technology company, CSDX is subject to stringent regulatory requirements for product development, approval, and marketing, particularly in regions like Europe and MENA. Compliance with these regulations is critical for market access and revenue generation.

What Investors Should Do

1. Monitor cash burn and future financing needs.
2. Evaluate the sustainability of reduced operating expenses.
3. Assess the revenue generation strategy.

Key Dates

• 2025-06-30: End of Six-Month Period — Reporting period for the 10-Q, showing improved net income but declining revenue and critically low cash.
• 2024-06-30: Prior Year Six-Month Period End — Comparison period for revenue and operating expenses, highlighting a significant drop in expenses and a rise in net income.
• 2024-12-31: Year-End 2024 — Previous balance sheet date, showing higher cash ($501) and current liabilities ($1,428) compared to the current period.

Glossary

Accumulated Deficit

The total net losses a company has incurred since its inception, minus any net profits. It represents a negative balance in retained earnings. (Indicates the company has historically operated at a loss and contributes to the going concern warning.)

Intangible Assets

Assets that lack physical substance but have value, such as patents, copyrights, trademarks, and goodwill. (These assets represent the overwhelming majority of CSDX's total assets, making their valuation critical.)

Going Concern

An accounting assumption that a business will continue to operate for the foreseeable future. If there is substantial doubt about this, it must be disclosed. (The company's financial condition raises significant doubt about its ability to continue as a going concern.)

Additional Paid-in Capital

The amount of money investors have paid for stock above its par or stated value. (A significant component of the company's equity, reflecting past capital raises.)

Professional Fees

Costs incurred for services provided by external professionals, such as lawyers, accountants, and consultants. (A significant reduction in these fees was the primary driver for the decrease in operating expenses.)

Year-Over-Year Comparison

Compared to the prior year's six-month period, CS DIAGNOSTICS CORP. has seen a substantial increase in net income, rising from $12,912 to $32,263, primarily due to a significant reduction in operating expenses from $85,505 to $38,887. However, this improvement is overshadowed by a 28% decrease in total revenues, which fell to $71,150 from $98,417, driven by lower diagnostic service activity and licensing income. The company's cash position has deteriorated further, reaching an alarmingly low $196, and it continues to face going concern risks due to a substantial accumulated deficit.

Key Financial Figures

• $0.001 — registered Common Stock, par value $0.001 per share CSDX OTCQB Preferred Stoc
• $0.00001 — of the registrant’s common stock, $0.00001 par value, issued and outstanding. 2
• $71,150 — he six months ended June 30, 2025, were $71,150, compared to $98,417 for the same perio
• $98,417 — une 30, 2025, were $71,150, compared to $98,417 for the same period in 2024, representi
• $38,887 — ing expenses decreased significantly to $38,887 for the six-month period ended June 30,
• $85,505 — -month period ended June 30, 2025, from $85,505 for the same period in 2024. The reduct
• $22,354 — dministrative expenses rose modestly to $22,354, reflecting increases in compliance-rel
• $32,263 — 025, the Company recorded net income of $32,263, compared with $12,912 in the prior-yea
• $12,912 — ed net income of $32,263, compared with $12,912 in the prior-year period. The improveme
• $499,431,377 — , 2025, the Company had total assets of $499,431,377, compared to $499,400,501 at December 3
• $499,400,501 — tal assets of $499,431,377, compared to $499,400,501 at December 31, 2024. The asset base co
• $499.4 million — y of intangible assets of approximately $499.4 million and additional paid-in capital contribu
• $196 — ders. Cash and cash equivalents totaled $196 as of June 30, 2025, compared to $501 a
• $501 — d $196 as of June 30, 2025, compared to $501 at year-end 2024. The Company reported
• $1,428 — lities as of June 30, 2025, compared to $1,428 in accounts payable as of December 31,

Filing Documents

• g10925010q.htm (10-Q) — 208KB
• ex31_1.htm (EX-31.1) — 10KB
• ex31_2.htm (EX-31.2) — 7KB
• ex32_1.htm (EX-32.1) — 4KB
• ex32_2.htm (EX-32.2) — 4KB
• cscorp_logo.jpg (GRAPHIC) — 14KB
• 0001214659-25-014817.txt ( ) — 254KB

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION 4

Financial Statements

Item 1. Financial Statements 4

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 10

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 12

Controls and Procedures

Item 4. Controls and Procedures 12

—OTHER INFORMATION

PART II—OTHER INFORMATION 13

Legal Proceedings

Item 1. Legal Proceedings 13

Risk Factors

Item 1A. Risk Factors 13

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 23

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 23

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 23

Other Information

Item 5. Other Information 23

Exhibits

Item 6. Exhibits 24

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements CS DIAGNOSTICS CORP. CSDX BALANCE SHEET FOR THE PERIOD ENDED June 30 2025 June 30, 2025 (Unaudited) December 31, 2024 (Audited) Assets Current Assets Cash 196 501 Other Receivables 31,181 - Total Current Assets $ 31,377 $ 501 Intangible Assets 499,400,000 499,400,000 Total Assets $ 499,431,377 $ 499,400,501 Liabilities and Stockholders’ Deficit Current Liabilities Account Payables - 1,428 Non-current liabilities - Total Liabilities $ 0 $ 1,428 Shareholder's Equity / (Deficit) Common stock, $0.00001 par value; 250,000,000 shares authorized,137,340,200 shares issued and outstanding as of June 30, 2025 1,373 1,373 Preferred stock Series A, $0.00001 par value;1,000,000 shares authorized, 10 shares issued and outstanding as of June 30, 2025 - - Preferred stock Series B, $0.00001 par value; 20,000,000 shares authorized, 19,992,575 shares issued and outstanding as of June 30, 2025 2,000 2,000 Preferred stock Series C, $0.00001 par value; 4,000,000 shares authorized, 0 shares issued and outstanding as of June 30, 2025 40 - Additional paid-in capital 504,163,629 504,163,629 Accumulated deficit (4,735,665 ) (4,767,928 ) Total Stockholders’ Equity /(Deficit) $ 499,431,377 $ 499,399,073 Total Liabilities and Stockholders' Equity /(Deficit) $ 499,431,377 $ 499,400,501 The accompanying notes are an integral part of these financial statements 4 FOR THE PERIOD ENDED JUNE 30, 2025 (Unaudited) For The Three Months Ended June 30 2025 For The Three Months Ended June 30 2024 For The Six Months Ended June 30 2025 For The Six Months Ended June 30 2024 Revenue 730 45,159 71,150 98,417 Revenue $ 730.00 $ 45,159.00 $ 71,150.00 $ 98,417.00 Operating Expenses Professional Fee 14 40,709 16,533 85,264 Research & Development expenses 0 0 General & Administrative Expenses 520 101 22,354 241 Total O

Management’s Discussion and Analysis of Financial

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. The following discussion and analysis of our financial condition and results of operations should be read together with our unaudited consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q. Our financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and reflect our current corporate structure and organization as if such structure had been in place throughout all periods presented. This discussion contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. Such factors include, among others, the risks described under “ Risk Factors ” in Part II, Item 1A of this Quarterly Report on Form 10-Q and elsewhere herein. Except as required by law, we undertake no obligation to revise or update any forward-looking statements to reflect events or circumstances occurring after the date of this report. 10 Overview CS Diagnostics Corp. (the “Company”) is a Wyoming-based corporation focused on improving therapeutic outcomes and minimizing side effects through innovative medical technologies. The Company collaborates with universities, research institutions, and healthcare professionals to develop, license, and commercialize diagnostic and therapeutic products. In addition, the Company provides international firms in the medical sector with regulatory approval services and market access throughout Europe and the MENA regions. During the six months ended June 30, 2025, the Company

Quantitative and Qualitative Disclosures About Market

Item 3. Quantitative and Qualitative Disclosures About Market Risk. Not applicable.

Controls and Procedures

Item 4. Controls and Procedures. Under the supervision and with the participation of our management, including our Principal Executive Officer (“PEO”) and Principal Financial Officer (“PFO”), we evaluated the effectiveness of the Company’s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of June 30, 2025. 12 Evaluation of Disclosure Controls and Procedures Based on this evaluation, our PEO and PFO concluded that the Company’s disclosure controls and procedures were effective as of June 30, 2025 in ensuring that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (ii) accumulated and communicated to the Company’s management, including the PEO and PFO, as appropriate to allow timely decisions regarding required disclosure. Changes in Internal Control over Financial Reporting The Company also carried out an evaluation, under the supervision and with the participation of management, including the PEO and PFO, of changes in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the fiscal quarter ended June 30, 2025. There were no changes in our internal control over financial reporting during the quarter ended June 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Forward-Looking Statements

Forward-Looking Statements This MD&A contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Factors that could cause such differences include, among others, those discussed under “Risk Factors” in Part II, Item 1A of this Report.

—OTHER INFORMATION

PART II—OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings. As of the date of this Report, the Company is involved in the following legal proce

View Full Filing

View this 10-Q filing on SEC EDGAR